Results 151 to 160 of about 306,642 (296)

Four women whose pioneering contributions to science have been largely overlooked. [PDF]

Elife
Thomann LM, Batut J.
europepmc   +1 more source

A muscular dystrophy associated with bi‐allelic LEMD2 variants: Expanding the genotype of nuclear envelopathies

Brain Pathology, EarlyView.
Proteomics‐guided exome re‐analysis identifies bi‐allelic variants in the nuclear envelope LEMD2 gene, expanding its phenotypic spectrum. Created in BioRender. Pauper, M. (2026) https://BioRender.com/xamvo92.
Marc Pauper, Heike Kölbel, Iakowos Karakesisoglou, Anne Schänzer, Johann Böhm, Rachel Thompson, Nicolai Kohlschmidt, Bernd Ringel, Gisèle Bonne, Katja Neuhoff, Andrea Gangfuß, Ozge Aksel Kilicarslan, Sergi Beltran Agullo, Andreas Hentschel, Ulrike Schara‐Schmidt, Hanns Lochmüller, Kiran Polavarapu, Andreas Roos   +17 more
wiley   +1 more source

Protocol to explore olfactory placode morphogenesis using an agent-based model. [PDF]

STAR Protoc
Demont V, Letort G, Sanchez D, Batut J.
europepmc   +1 more source

Imaginative biology [PDF]

Nature, 1992
openaire   +2 more sources

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, EarlyView.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

Correction: Salinas-Giegé et al. tRNA Biology in Mitochondria. <i>Int. J. Mol. Sci.</i> 2015, <i>16</i>, 4518-4559. [PDF]

Int J Mol Sci
Salinas-Giegé T, Giegé R, Giegé P.
europepmc   +1 more source

Delivery of nano‐formulated drugs to solid tumours is selectively increased by co‐application of the vascular disrupting agent CA4P

British Journal of Pharmacology, EarlyView.
Background and purpose Nano‐formulated chemotherapeutics prolong systemic availability of drugs and can reduce systemic toxicity, but their accumulation in solid tumours is often limited and unpredictable. Broadly applicable strategies to selectively enhance tumour delivery are lacking.
Annabel Kitowski, Constanze Heise, Stefanie Sperling, Jasmin Hotz, Danica Bajic, Marina Rubey, Kathrin Klar, Georg Höfner, Julien Vollaire, Veronique Josserand, Jean‐Luc Coll, Oliver Thorn‐Seshold, Petar Marinković, Julia Thorn‐Seshold   +13 more
wiley   +1 more source

Identification of the novel c.149-8C>G splicing variant in RHCE*02 that weakens C antigen expression. [PDF]

Transfusion
Tournamille C, Fichou Y, Benech C, Braga GN, Devaux L, Flahaut R, Floch A.   +6 more
europepmc   +1 more source

Expanding the Phenotypic Spectrum Associated With Loss‐of‐Function SMARCA4 Variants to Eye Developmental Anomalies

Clinical Genetics, EarlyView.
This study expands the clinical spectrum of SMARCA4 by describing a novel phenotype in three unrelated individuals with truncating variants. Distinct from Coffin–Siris syndrome and rhabdoid tumor predisposition, this new association is characterized by ocular malformations, specifically microphthalmia and coloboma.
Bertrand Chesneau, Marjolaine Willems, Abdelhakim Bouazzaoui, Léopoldine Lequeux, Julie Plaisancié, Salima El Chehadeh, Hélène Dollfus, Nicolas Chassaing   +7 more
wiley   +1 more source

Feasibility of <i>TP53</i>-Mutated ctDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS. [PDF]

Cancers (Basel)
Marlin R, Jean-Laurent M, Joachim C, Vallard A, Pennont S, Suez-Panama V, Rose M, Ulric-Gervaise S, Lusbec S, Bera O, Aline-Fardin A, Ebring C.   +11 more
europepmc   +1 more source